Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

NCT00366418 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: Rituximab

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)